Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07796126 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status

Name: Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status — clinical trial record (NCT07796126)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: HNSCC

StatusNot Yet Recruiting

PhasePhase 2

SponsorBarbara Ann Karmanos Cancer Institute

Started2026-09-30

View on ClinicalTrials.gov ↗

The goal of this clinical trial is to learn if the drug Toripalimab can prime the tumor to optimize response to Paclitaxel in HNSCC patients with a decrease performance status in a way that make both drugs well tolerated and improve partial or complete response rate over each treatment. The main questions it aims to answer are: * What is the response rate of the cancer to paclitaxel after priming with toripalimab * What is the time to progression if we continue to cycle between toripalimab and paclitaxel * What is the impact on the patient's quality of life and overall survival

Trial Details

NCT Number	NCT07796126
Lead Sponsor	Barbara Ann Karmanos Cancer Institute
Conditions	Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Enrollment	22 participants
Start Date	2026-09-30
Primary Completion	2028-05-29 (estimated)
Study Completion	2029-05-29 (estimated)
Updated on ClinicalTrials.gov	2026-08-31